Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GDC-0339 is discovered as a potential treatment of multiple myeloma. GDC-0339 is an orally bioavailable and well-tolerated inhibitor of the pan-Pim kinase (Kis: 0.03 nM, 0.1 nM, and 0.02 nM for Pim1, Pim2, and Pim3, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,650.00 | |
50 mg | 10-14 weeks | $ 2,150.00 | |
100 mg | 10-14 weeks | $ 3,730.00 |
Description | GDC-0339 is discovered as a potential treatment of multiple myeloma. GDC-0339 is an orally bioavailable and well-tolerated inhibitor of the pan-Pim kinase (Kis: 0.03 nM, 0.1 nM, and 0.02 nM for Pim1, Pim2, and Pim3, respectively). |
Targets&IC50 | Pim1:0.03 nM(Ki), Pim3:0.02 nM(Ki), Pim2:0.1 nM(Ki) |
In vitro | GDC-0339 is cytostatic (IC50 of 0.1 μM for MM.1S cells). GDC-0339 treatment shows a constellation of Pim downstream signaling events. Which is consistent with inhibition of Pim kinases[2]. |
In vivo | GDC-0339 has a half-life of t1/2=0.9 h. GDC-0339 (1-300 mg/kg; p.o; daily; for 21 days) is potently in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models [2]. |
Molecular Weight | 465.5 |
Formula | C20H22F3N7OS |
CAS No. | 1428569-85-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (107.41 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GDC-0339 1428569-85-0 Chromatin/Epigenetic JAK/STAT signaling Pim Pim kinases inhibit GDC 0339 GDC0339 Inhibitor inhibitor